Gut Fungus Linked to Alcohol Aversion, Offering New Hope for Addiction Treatment
A groundbreaking new study reveals a surprising connection between the gut fungus Candida albicans and alcohol use disorder (AUD), potentially paving the way for innovative treatment approaches. Researchers at Tufts University have discovered that the presence of this common fungus can alter the brain’s reward pathways, leading to a rapid aversion to alcohol in mice.
Researchers Carol Kumamoto, PhD, and Andrew Day, PhD, shared their findings with Psychiatric Times, detailing how C. albicans impacts dopamine signaling and ultimately influences drinking behavior. This research builds upon a decade of work demonstrating increased levels of C. albicans in individuals struggling with AUD and its contribution to alcoholic liver disease.
The Gut-Brain Connection: A Fungal Influence
The study, published in mBio, involved colonizing mice with C. albicans and observing their ethanol consumption. The results were striking: mice with the fungal colonization consumed significantly less alcohol than their non-colonized counterparts. “We found that C. albicans-colonized mice showed greater effects of ethanol intoxication when given the same amount of alcohol as mock-colonized mice,” explained one of the researchers. This heightened sensitivity contributed to the development of an aversion to alcohol.
Crucially, the researchers identified prostaglandin E2 (PGE2) as a key player in this process. Blocking PGE2 receptors reversed the effects of colonization, demonstrating its critical role in mediating the behavioral changes. Furthermore, colonized mice exhibited alterations in dopamine receptors within the dorsal striatum – a brain region central to reward and motivation – indicating a fundamental shift in their relationship with alcohol.
A Rapid Response: The Speed of Change
What surprised the research team was the speed at which these changes occurred. “It was surprising that when C. albicans was introduced into mice, their drinking behavior was altered very quickly, within 24 hours,” a researcher noted. This rapid response suggests a direct and potent interaction between the fungus and the brain. The team also observed a similar swift effect when studying the fungus’s impact on anxiety-like behaviors in mice, reinforcing the idea that C. albicans exerts a quick and significant influence on host behavior.
Implications for Alcohol Use Disorder Treatment
These findings contribute to a growing body of evidence highlighting the crucial role of the gut microbiome in substance use disorders. The research establishes gut fungi as significant contributors to the gut-brain axis in AUD, expanding our understanding of the complex factors driving addiction.
The potential for novel therapies is significant. Researchers suggest that future treatments for substance use disorders (SUDs) – including those involving cocaine and other drugs – may need to consider the effects of the microbiome on an individual’s ability to maintain abstinence. Fecal microbiota transplant (FMT), a procedure gaining traction in medical research, has already shown promise in reducing cravings in individuals with AUD, as demonstrated by the work of Dr. Jasmohan Bajaj’s group at VCU.
Future Directions and the Role of Diet
While the current study focused on mice, researchers are eager to explore whether these findings translate to human patients. Further investigation is needed to determine if manipulating the gut microbiome could offer a new therapeutic avenue for those struggling with AUD.
The link between diet and the microbiome also warrants further exploration. “We know that diet can affect the composition of the microbiome very dramatically, and our results and those of others in the field argue that organisms in the microbiome can affect host behavior,” one researcher explained. This raises the possibility that dietary interventions could be used to modulate the microbiome and potentially influence alcohol consumption patterns.
For psychiatrists working with patients with AUD, this research underscores the complexity of the disorder. “Works like ours reiterate the notion that there are myriad variables that contribute to factors that drive SUD,” researchers emphasized. They suggest that microbiome-based therapies could be particularly helpful for individuals who have exhausted traditional treatment options, offering a potential lifeline for those struggling to maintain sobriety. .
Dr. Kumamoto is a professor of molecular biology and microbiology at Tufts University. Dr. Day performed this work as a PhD candidate in molecular microbiology, working with Dr. Kumamoto.
